曲妥珠单抗对乳腺癌术后新辅助化疗患者血清TIMP-1/2、MMP-2/9的影响

Curative Efficacy of Trastuzumab in Postoperative Neoadjuvant Chemotherapy for Breast Cancer Patients and Its Effects on Serum Timp-1/2 and Mmp-2/9

目的探讨曲妥珠单抗在乳腺癌患者术后新辅助治疗中的疗效及对血清组织金属蛋白酶抑制剂-1(TIMP-1)、组织金属蛋白酶抑制剂-2(TIMP-2)、基质金属蛋白酶2(MMP-2)、基质金属蛋白酶9(MMP-9)的影响。方法选择乳腺癌术后患者52例作为研究对象,以随机数表法分为观察组(n=30)和对照组(n=22),对照组使用顺铂进行治疗,观察组在对照组得到基础上采用曲妥珠单抗进行治疗。比较两组治疗后疗效及血清TIMP-1、TIMP-2、MMP-2、MMP-9、血管内皮生长因子A(VEGFA)、血管内皮生长因子B(VEGFB)、血管内皮生长因子C(VEGFC)、血清癌胚抗原(CEA)、糖类抗原125(CA-125)、糖类抗原153(CA15-3)水平变化情况及不良反应发生情况。结果治疗后,观察组临床疗效总有效率96.67%显著高于对照组的77.27%(P<0.05);两组患者治疗前血清血清TIMP-1、TIMP-2、MMP-2、MMP-9水平无明显差异;治疗后,两组患者血清TIMP-1、TIMP-2、MMP-2、MMP-9水平均明显下降,且观察组血清TIMP-1、TIMP-2、MMP-2、MMP-9水平显著低于对照组,(P<0.05);两组患者治疗前血清VEGFA、VEGFB、VEGFC水平无明显差异;治疗后,两组患者血清VEGFA、VEGFB、VEGFC水平均明显下降,且观察组血清VEGFA、VEGFB、VEGFC水平显著低于对照组,(P<0.05);两组患者治疗前血清肿瘤标记物水平无明显差异;治疗后,两组患者血清肿瘤标记物水平均明显下降,且观察组乳腺组织CEA、CA-125、CA15-3水平显著低于对照组,(P<0.05);观察组不良反应总发生率为26.67%,明显低于对照组的77.27%,(P<0.05)。结论曲妥珠单抗联合新辅助治疗疗效显著,可以有效的降低血清TIMP-1、TIMP-2、MMP-2、MMP-9水平,值得推广与运用。

Objective To study the curative efficacy of trastuzumab in Postoperative neoadjuvant chemotherapy for breast cancer patients and its effectson serum tissue protease inhibitor-1(timp-1),Tissue protease inhibitor-2(timp-2),Matrix metalloproteinase 2(mmp-2),Matrix metalloproteinase 9(mmp-9).Methods 52 cases of postoperative breast cancer patients were selected as subjects,and divided into the observation group(n=30)and the control group(n=22).The control group was treated with cisplatin,and the observation group was treated with trastuzumab on the basis of the control group.Comparing the 2 groups after treatment efficacy and serum TIMP 1 and TIMP-2,MMP-2,MMP-9,vascular endothelial growth factor(VEGFA),vascular endothelial growth factor B(VEGFB),vascular endothelial growth factor C(VEGFC),serum carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA-125),carbohydrate antigen 125(CA15-3)level changes and adverse reactions occur.Results After treatment,the total effective rate of the observation group was 96.67%,which was significantly higher than the control group's 77.27%(P<0.05).There was no significant difference in serum timp-1,timp-2,mmp-2 and mmp-9 levels between the 2 groups before treatment.After treatment,serum levels of timp-1,timp-2,mmmp-2 and mmp-9 in both groups decreased significantly,and serum levels of timp-1,timp-2,mmp-2 and mmmp-9 in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in serum VEGFA,VEGFB and VEGFC levels between the 2 groups before treatment.After treatment,serum VEGFA,VEGFB and VEGFC levels of both groups significantly decreased,and serum VEGFA,VEGFB and VEGFC levels of the observation group were significantly lower than those of the control group(P<0.05).There was no significant difference in serum tumor markers between the 2 groups before treatment.After treat ment,the levels of tumor markers in both groups were significantly decreased,and the levels of CEA,ca-125,and ca15-3 in the breast tissue of the observation group were significantly lower than those of the control group(P<0.05).The total incidence of adverse reactions in the observation group was 26.67%,significantly lower than the control group's 77.27%(P<0.05).Conclusion Trastuzumab combined with neoadjuvant chemotherapy has significant curative effect and can effectively reduce serum levels of timp-1,timp-2,mmp-2 and mmp-9,which is worthy of promotion and application.